In later-line treatment of SCLC, anti-PD-1 agents (pembrolizumab or nivolumab) as third- or later-line treatment provided duration of response of ~ 18 months and ORR of 12-33.3% [5, 23]. The gene discussed is PDCD1; the disease is small cell lung carcinoma.